Mobile

The study investigates the new subcutaneous application of Triptorelin pamoate (Pamorelin® LA 11.25 mg) versus the intramuscular application in patients with advanced prostate cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-019632-12

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objective of the trial is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-85d] for serum testosterone in patients with advanced prostate cancer.

Critère d'inclusion

  • advanced prostate cancer (locally advanced or metastatic)

Liens